MACROD1

MACROD1 (LRP16) is a mono-ADP-ribose hydrolase whose single macro domain serves dual roles as an enzyme that reverses ADP-ribosylation and as a protein-interaction module integrating it into nuclear transcription and DNA-damage signaling (PMID:29410655, PMID:32683309, PMID:17914104). As a catalyst, it removes ADP-ribose from phosphorylated double-stranded DNA ends, and its crystal structure in complex with ADP-ribose defines a β5-α10 switch loop in which Phe272 orients the distal ribose and a conserved hydrogen-bond network positions the catalytic water; this hydrolase activity supports its recruitment to ADP-ribosylated DNA lesions and contributes to DNA damage repair (PMID:29410655, PMID:32683309). Independently of catalysis, the macro domain binds the AF-1 domain of estrogen receptor α and binds androgen receptor, acting as a transcriptional coactivator that amplifies hormone-driven transcription and, in an ERα-dependent manner, represses E-cadherin to promote invasive growth (PMID:17914104, PMID:19022849, PMID:17893710). MACROD1 also functions in NF-κB signaling, associating with the p65 subunit to stabilize the nuclear NF-κB/p300/CBP complex and residing in a constitutive PARP1/IKKγ preassembly complex required for DSB-induced IKKγ modification and NF-κB activation; it further scaffolds a PKR–IKKβ ternary complex that prolongs PAR-dependent NF-κB transactivation and confers chemoresistance (PMID:21483817, PMID:25735744, PMID:28820388). The protein is enriched in mitochondria, particularly in skeletal muscle, where its loss disrupts mitochondrial morphology, and it suppresses PARP1-mediated NAD+ consumption to activate SIRT3-dependent antioxidant signaling protective against diabetic cardiomyopathy (PMID:29410655, PMID:32427867, PMID:38459256). Its nuclear availability is controlled by keratin 18, which sequesters it in the cytoplasm to limit ERα signaling (PMID:20035625).

1. 2007 High

   Established MACROD1 as a hormone-receptor coactivator by showing its macro domain binds the ERα AF-1 domain and amplifies ERα-driven transcription, defining its first molecular function.

   Evidence GST pulldown, CoIP, mammalian two-hybrid, and luciferase reporter with siRNA knockdown across cell lines

   PMID:17914104

   Open questions at the time

   • Did not test whether catalytic/enzymatic activity is involved in coactivation
   • Structural basis of macro domain–AF-1 contact not resolved
2. 2007 Medium

   Connected MACROD1 coactivation to an oncogenic output by showing it represses E-cadherin transcription in an ERα-dependent manner to promote endometrial cancer invasion.

   Evidence Transwell invasion, promoter-luciferase, and ChIP with siRNA/ectopic expression in Ishikawa cells

   PMID:17893710

   Open questions at the time

   • Mechanism by which MACROD1 antagonizes ERα at the E-cadherin promoter unresolved
   • Single cell-line context
3. 2007 Medium

   Defined a feedforward loop in which estrogen induces MACROD1 expression itself, via ERα/Sp1 cooperation at its proximal promoter.

   Evidence Promoter deletion/mutation luciferase, Sp1-siRNA, EMSA, and ChIP

   PMID:18206366

   Open questions at the time

   • In vivo relevance of the autoregulatory loop not tested
4. 2008 High

   Generalized the coactivator role beyond ERα by showing the single macro domain is sufficient for androgen receptor coactivation and is required for androgen-driven prostate cancer cell proliferation.

   Evidence CoIP, domain mapping, luciferase reporter, RNAi rescue in AR-positive vs AR-negative cell lines

   PMID:19022849

   Open questions at the time

   • Whether the same domain surface mediates both ERα and AR binding not determined
5. 2009 High

   Identified a spatial control mechanism: keratin 18 sequesters MACROD1 in the cytoplasm to limit its nuclear ERα coactivation.

   Evidence Yeast two-hybrid, GST pulldown, CoIP, GFP localization, nuclear/cytoplasmic fractionation, BrdU assay

   PMID:20035625

   Open questions at the time

   • Signals that release MACROD1 from K18 sequestration unknown
6. 2011 High

   Extended MACROD1 into NF-κB signaling by showing it associates with p65 to stabilize the nuclear NF-κB/p300/CBP complex rather than affecting nuclear translocation.

   Evidence GST pulldown, CoIP, luciferase reporter, RNAi, Annexin V flow cytometry

   PMID:21483817

   Open questions at the time

   • Whether enzymatic ADP-ribose hydrolysis contributes to complex stabilization not addressed
7. 2013 Medium

   Linked MACROD1 to metabolic signaling by showing it negatively regulates insulin signaling through mTOR-dependent TNF-α secretion and IRS-1/PI3K/Akt suppression.

   Evidence Lentiviral knockdown/overexpression in 3T3-L1 adipocytes, glucose uptake, phospho-Western, rapamycin epistasis

   PMID:23389992

   Open questions at the time

   • Direct molecular link between MACROD1 and mTOR activation not defined
8. 2015 High

   Defined a constitutive PARP1/IKKγ preassembly platform centered on MACROD1 required for DSB-induced IKKγ SUMOylation/phosphorylation and downstream NF-κB activation.

   Evidence Reciprocal CoIP, knockdown with NF-κB activation assays, DSB induction, Ku70/Ku80 epistasis

   PMID:25735744

   Open questions at the time

   • Whether ADP-ribose hydrolase activity is required for scaffold function untested
9. 2017 High

   Showed MACROD1 scaffolds a PKR–IKKβ ternary complex that prolongs PAR-dependent NF-κB transactivation and drives chemoresistance, identifying a druggable interaction.

   Evidence CoIP, MRS2578 competition, NF-κB reporter, xenograft models

   PMID:28820388

   Open questions at the time

   • How PKR activation relates to MACROD1 enzymatic activity unclear
10. 2018 High

    Established MACROD1 as a mitochondria-enriched mono-ADP-ribose hydrolase acting on phosphorylated dsDNA ADP-ribose adducts, anchoring its enzymatic identity and localization.

    Evidence Subcellular fractionation of endogenous protein and in vitro hydrolase assay with defined dsDNA substrates

    PMID:29410655

    Open questions at the time

    • Physiological mitochondrial substrates not identified
    • Reconciliation of mitochondrial localization with nuclear coactivator roles not addressed
11. 2018 Medium

    Placed MACROD1 in adipocyte inflammatory signaling via a Rac1-dependent ERK1/2 pathway promoting cytokine expression.

    Evidence LC-MS proteomics, phospho-Western, siRNA of MACROD1 and Rac1, PD98059 inhibition

    PMID:30562745

    Open questions at the time

    • Direct interaction between MACROD1 and Rac1 not demonstrated
12. 2020 High

    Solved the catalytic mechanism: the crystal structure with ADP-ribose defined the β5-α10 switch loop, Phe272 substrate orientation, and a hydrogen-bond network positioning catalytic water, with recruitment to ADP-ribosylated DNA lesions required for repair.

    Evidence X-ray crystallography, catalytic-residue mutagenesis, in vitro hydrolase assay, laser-induced DNA damage recruitment

    PMID:32683309

    Open questions at the time

    • In vivo DNA repair contribution relative to paralogs not quantified
13. 2020 High

    Confirmed predominant mitochondrial localization with a KO morphology phenotype and a mitochondria-concentrated interactome implicating mitochondrial RNA metabolism.

    Evidence Validated monoclonal antibodies, immunofluorescence, KO morphology assessment, BioID proximity labeling

    PMID:32427867

    Open questions at the time

    • Specific role in mitochondrial RNA metabolism not functionally demonstrated
14. 2021 Medium

    Linked MACROD1 loss to a female-specific motor-coordination defect, providing organismal evidence consistent with its mitochondrial role.

    Evidence Macrod1/Macrod2 knockout mice with behavioral battery testing

    PMID:33578760

    Open questions at the time

    • No molecular mechanism linking enzymatic activity to the behavioral phenotype
    • Basis of sex-specificity unexplained
15. 2024 Medium

    Defined a protective mitochondrial axis in which MACROD1 suppresses PARP1 to preserve NAD+ and activate SIRT3-dependent antioxidant signaling against diabetic cardiomyopathy.

    Evidence Macrod1 KO and cardiac-specific overexpression mouse models, NAD+ measurement, PARP1/SIRT3 Western, mitochondrial function assays

    PMID:38459256

    Open questions at the time

    • Whether MACROD1 hydrolase activity drives PARP1 suppression not resolved
    • Direct mechanism of PARP1 downregulation unclear

• How a single macro domain reconciles its catalytic ADP-ribose hydrolase function with its non-catalytic scaffolding/coactivator roles, and which activity dominates in each subcellular compartment, remains unresolved.
• No study has tested whether catalytic mutants retain coactivator/scaffold function
• Physiological in vivo substrates of the hydrolase not identified
• Mechanism partitioning nuclear vs mitochondrial pools beyond K18 sequestration unknown